ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.
No risks detected for ACAD from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$17.51|
|52 Week High||US$15.68|
|52 Week Low||US$57.46|
|1 Month Change||8.62%|
|3 Month Change||-25.49%|
|1 Year Change||-58.91%|
|3 Year Change||-21.16%|
|5 Year Change||-30.90%|
|Change since IPO||161.34%|
Recent News & Updates
Acadia Pharmaceuticals: Refunding A Former Champion
Acadia was blindsided by NUPLAZID’s CRL for treating hallucinations and delusions linked with dementia-related psychosis “DRP”. The loss of all expected near-term DRP sales chopped the share price in half. COVID-19 has hurt in-person patient office visits, which has hindered commercial growth. However, the company was able to find some encouraging trends in their Q2 earnings results. Despite the strong headwinds and regulatory risks, I am willing to refund a previous winner in anticipation the market will recognize the company’s intrinsic value in the coming years.
Acadia's Essential Questions Heading Into Q2 2021 Earnings
So far Acadia has had a rough H1 2021; whether or not things will get better during H2 is the biggest question. Its prognosis depends in part on assessing the cause for Acadia's last minute unexpected and unexplained CRL, bureaucratic bungling by the FDA, management action, or questionable trial design. One plausible possibility is that the trial design included a problem issue from the start that was not recognized until the very end. Acadia reports Q2 2021 earnings on 08/04/2021 after a mixed string of earnings reports with muted expectations.
|ACAD||US Biotechs||US Market|
Return vs Industry: ACAD underperformed the US Biotechs industry which returned 12.4% over the past year.
Return vs Market: ACAD underperformed the US Market which returned 27.6% over the past year.
Stable Share Price: ACAD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ACAD's weekly volatility (6%) has been stable over the past year.
About the Company
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder.
ACADIA Pharmaceuticals Fundamentals Summary
|ACAD fundamental statistics|
Is ACAD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ACAD income statement (TTM)|
|Cost of Revenue||US$282.79m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.63|
|Net Profit Margin||-56.49%|
How did ACAD perform over the long term?See historical performance and comparison
Is ACADIA Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ACAD ($17.51) is trading below our estimate of fair value ($182.32)
Significantly Below Fair Value: ACAD is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ACAD is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ACAD is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ACAD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ACAD is overvalued based on its PB Ratio (5x) compared to the US Biotechs industry average (2.9x).
How is ACADIA Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACAD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: ACAD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ACAD's is expected to become profitable in the next 3 years.
Revenue vs Market: ACAD's revenue (25.5% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: ACAD's revenue (25.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ACAD's Return on Equity is forecast to be low in 3 years time (10.6%).
How has ACADIA Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ACAD is currently unprofitable.
Growing Profit Margin: ACAD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ACAD is unprofitable, but has reduced losses over the past 5 years at a rate of 0.8% per year.
Accelerating Growth: Unable to compare ACAD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACAD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: ACAD has a negative Return on Equity (-46.34%), as it is currently unprofitable.
How is ACADIA Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: ACAD's short term assets ($645.7M) exceed its short term liabilities ($95.3M).
Long Term Liabilities: ACAD's short term assets ($645.7M) exceed its long term liabilities ($64.3M).
Debt to Equity History and Analysis
Debt Level: ACAD is debt free.
Reducing Debt: ACAD has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACAD has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ACAD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is ACADIA Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ACAD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ACAD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ACAD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACAD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ACAD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Davis (60 yo)
Mr. Stephen R. Davis, also known as Steve, J.D., serves as the Director at Heron Therapeutics Inc. since October 2019. He has been the Chief Executive Officer of ACADIA Pharmaceuticals, Inc. since Septembe...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD7.76M) is above average for companies of similar size in the US market ($USD5.19M).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
Experienced Management: ACAD's management team is considered experienced (2.8 years average tenure).
Experienced Board: ACAD's board of directors are considered experienced (5.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
ACADIA Pharmaceuticals Inc.'s employee growth, exchange listings and data sources
- Name: ACADIA Pharmaceuticals Inc.
- Ticker: ACAD
- Exchange: NasdaqGS
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.813b
- Shares outstanding: 160.64m
- Website: https://www.acadia-pharm.com
Number of Employees
- ACADIA Pharmaceuticals Inc.
- 12830 El Camino Real
- Suite 400
- San Diego
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 22:02|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.